Blackrock
BlackRock is a global investment management corporation headquartered in New York City, specializing in a diverse array of asset classes and investment strategies. The firm manages equity, fixed income, and balanced mutual funds, along with hedge funds and exchange-traded funds. BlackRock also provides investment advisory services and engages in private equity and venture capital through its subsidiaries, focusing on direct investments and fund of funds across various sectors, including natural resources. The firm caters to a wide range of clients, from large institutions to individual investors, aiming to help them achieve their financial goals. With a commitment to transparency and client service, BlackRock has become the largest asset manager in the world, overseeing trillions of dollars in assets. Its global presence is supported by offices in key financial hubs, allowing it to address the unique needs of clients across different regions.
MNTN is a provider of cloud-based advertising software designed for direct marketers, agencies, and brands of all sizes. Its comprehensive advertising suite enables users to effectively launch retargeting and prospecting campaigns across various platforms, including display, mobile, and social media. Additionally, MNTN offers a creative suite that empowers users to design visually appealing advertisements utilizing available content. The platform is known for its emphasis on transparency and control, allowing advertisers to manage their campaigns efficiently with one of the fastest go-live times in the industry. MNTN has received multiple accolades for its innovative solutions and workplace culture, establishing itself as a prominent player in the digital advertising landscape.
TScan Therapeutics is a biopharmaceutical company dedicated to developing innovative T cell therapies to treat various cancers, including liquid tumors and solid tumors. The company focuses on engineering T cell receptor (TCR) therapies, with specific candidates aimed at addressing hematologic malignancies and preventing relapse after hematopoietic stem cell transplantation. TScan utilizes a specialized platform that identifies shared T cell antigens and minimizes off-target effects, enhancing the safety and effectiveness of its treatments. The company’s pipeline includes both liquid tumor therapies and multiplexed TCR-T candidates for solid tumors. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and comprises a team of experts committed to expanding treatment options for patients with limited therapeutic alternatives.
Tennenbaum Waterman Fund is a direct lending fund managed by Tennenbaum Capital Partners, LLC, a prominent alternative investment management firm founded in 1999. Based in Santa Monica, California, the fund focuses on investments across North America and Europe, targeting sectors such as commercial products, commercial services, financial services, business products, cleantech, and industrial sectors. Tennenbaum Capital Partners has established a strong track record in credit opportunities, having invested approximately $9 billion in over 170 portfolio companies through various strategies, including specialty funds focused on debtor-in-possession financing. With about $5 billion in capital under management, the firm is well-positioned to pursue diverse investment opportunities while maintaining a commitment to performance and strategic growth.